The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
December is here; the end of 2023 fast approaches. For those operating in the life sciences sector, it’s all too clear that the time has come for 2024 industry predictions.
Eleven new digital health start-ups have graduated from PharmStars’ twice-yearly education and mentoring programme, with the latest crop focusing on digital innovations in
At the start of this year, Aeglea BioTherapeutics was looking like it may go out of business.
Views & Analysis
White Papers & Webinar
Podcasts & Video
Accelerate Next Generation RNAs into Safe & Effective Clinical Candidates with Therapeutic Potentials Across All Diseases by Overcoming Quality, Stability, & Large-Scale Manufacturi
Enhance Speed, Purity & Scalability of Your Process Development & Manufacturing to Improve Functionality, Efficacy & Approval Rate of mRNA Drugs Across All Disease Indication
180+ Technical mRNA Specialists | 35+ Expert Speakers | 2 Content Streams
The surge of clinical breakthroughs in SGLT2s, GLP-1s and ERAs for CKD, significant advancements to strengthen proteinuria and GFR slope as surrogates for long-term outcomes, and a wave of
With the recent double whammy of Bayer and Novartis both strategically investing in Bicycle Therapeutics to develop radioconjugates for oncology targets; mergers, acquisitions and collabora